agora financial is a privately held publishing company , based in baltimore , maryland , that produces print and email publications , books , and conferences directed toward providing financial advice , commentary , and marketing predictions .

agora financial

glassdoor has 16 agora financial reviews submitted anonymously by agora financial employees . read employee reviews and ratings on glassdoor to decide if agora financial is right for you .
about agora financial . agora financial is all about
fat - tail
ideas . all work will be in - house at the agora financial office in baltimore . . . .
agora financial has been a leading innovator in the financial advice industry for over 25 years .
fleet street publications limited and agora financial uk limited are both companies under agora inc . you may already know of agora’s founder : bill bonner .
but your editors and experts from agora financial are on a more serious mission .
copyright © 2008 agora financial llc . all rights reserved . the content of this site may not be redistributed without the express written consent of agora , inc . website designed and maintained by agora financial .
© 2018 agora financial uk ltd , 5 - 11 worship street , london ec2a 2bh . | agora financial uk ltd is authorised and regulated by the financial conduct authority . fca no 115234 . agora financial uk ltd is registered in england and wales company no 1937374 . vat no gb629 7287 94 .
agora financial provides independent economic commentary through print and online publications , print and e - books , films and international conferences . for over 25 years , agora financial has been a leading innovator in the financial publishing industry .
the financial ideas that are discussed by the speakers at our symposiums and conferences have made agora financial events among the most highly regarded and sought - after in the financial world .
addison wiggin is the executive publisher of agora financial , llc , a fiercely independent economic forecasting and financial research firm based in baltimore , md . he’s the creator and editorial director of agora financial’s daily 5 min . forecast and editorial director of agora’s flagship publication the daily reckoning .
now in its 10th anniversary year , the daily reckoning is the flagship e - letter of baltimore - based financial research firm and publishing group agora financial , a subsidiary of agora inc .
agora financial llc . all rights reserved . the content of this site may not be redistributed without the express written consent of agora , inc .
agora financial has been a leading innovator in the financial publishing industry for nearly two decades — correctly predicting some of wall street and washington’s biggest moves .
even we’re stunned by this one . agora financial is gearing up for their first ever media buyer bootcamp .
laissez faire books is a division of agora financial . copyright © 2018 creative commons , attribution | privacy | whitelist us
… the agora financial investment symposium will be held in that fine city july 20 - 23 , 2010 . it’s been
agora financial provides independent economic and alternative health ideas to help everyday folks live a more independent , healthy and wealthy life .
xl financial assurance ltd . and xl group assurance inc . receive aaa financial strength rating from moody ' s investor services
for the next couple of days i will be attending the 2011 agora financial investment symposium in vancouver where i will be hosting a series of video interviews with some of my favourite financial authors .
continually expand your knowledge of the agora businesses . understanding the agora companies world will allow publishing services to better serve them . . . .
agora financial provides independent economic commentary , analysis and education through print and online publications , videos , online seminars , conference calls and more .
agora financial’s world - class analysts and publications help you secure your financial independence so you can live the life you deserve . watch the video , then sign up below to learn more about how we can help .
1 ) first , by letting you read the letter , i am not giving away any of agora ' s proprietary secrets . you could not
steal
this letter if you wanted to . it ' s agora and only agora who has steve sarnoff and the incredible financial service he provides .
[ . . . ] impact investing : experts weigh in on financial return & social goodwhat are the top five personal finance and investment traps ? | bruce brammall financialinvestment products — boulos financial group - groupe financier bouloshedging against investment riskthe elephant eater investment plan and asset allocation | eat the financial elephant2013 agora financial investment symposium | sprott money blog [ . . . ]
three time best - selling author , producer and writer of the acclaimed documentary i . o . u . s . a . and founder of agora financial
it’s the color on the internal sales report of one of the fastest growing financial publishing groups part of the agora companies … banyan hill . . . .
in late 2010 , mr . wiggin became the president of laissez faire books , the nation’s premier libertarian bookseller , when the company was acquired by agora financial .
you have gained access to a wealth of information that could shape your financial perspective for decades to come . you now have access to : our new high - definition video recordings and the digital . mp3s of the 2012 agora financial investment symposium
william bonner , president and founder , agora inc . the declining marginal utility of stuff
) convene a who’s who of investment analysts at the agora financial investment symposium in vancouver , b . c . the event in 2009 marks the 10th anniversary of both
we hope that you are able to join us at the 2013 agora financial investment symposium . you can find more details about this event by clicking the link below :
world financial seminars launches one of its first wealth cruises , traveling to alaska .
agora has decent pay with plenty of incentives and commission opportunities . agora also provides a great work environment that doesn ' t feel like your a typical office . lots of company unity
agora financial provides a unique environment where hard work , creativity , and innovation are the norm . the entrepreneurial atmosphere and ability to create your own path make for a refreshing corporate culture . there ' s a reason agora inc is always rated by the sun as one of the best place to work in baltimore . great people + great culture = agora .
being a part of our team , and an employee of the agora , is an opportunity that’s highly sought after . the agora is comprised of more than 800 professionals in . . .
our honest , unbiased and independent financial forecasts have been recognised by numerous media sources including the wall street journal , the economist , reuters , the financial times and many more .
“an explosive critique about the investment industry : provocative and well worth reading . ” financial post
on march 17 , 2011 , agora financial llc , a publisher of books and newsletters on economics and investments , acquired laissez faire books from the international society for individual liberty ( isil ) .
data entry , metals cabinet , athenian agora excavations ( director : john camp ii ) . 2002 .
agora financial uk is currently seeking a publisher to lead our london - based financial publishing group . we are looking for a senior - level marketing professional with significant experience managing a direct response business . the ideal candidate will be an ideas - driven leader - - someone who can dev . . .
the culture at agora financial is fast paced and innovative ideas are the norm . if you require excessive hand holding or if you aren’t open to challenging yourself , this might not be the place for you .
and since we don’t want you to miss out on being here yourself next year , we’re throwing in a complimentary bonus gift : a $ 100 gift certificate to join us here in vancouver next year , or to come to any conference offered by agora financial or our affiliated company agora travel in the next 12 months .
the theme for this year’s symposium is
the tale of two americas
and is sure to feature some controversially and insightful presentations . below is a brief description of the upcoming event , provided by agora financial :
on tuesday night at the conference we will be seeing a special screening of agora’s latest documentary “risk ! ” .
louis basenese is promoted to investment director of the new white cap research group , an agora inc . affiliate .
greek imperial bronzes from the athenian agora , an article in process soon to be submitted to the journal hesperia .
agora entertainment is the production company behind the critically - acclaimed documentary film i . o . u . s . a . which was concieved of , co - written and executive produced by agora financial’s addison wiggin . in july 2008 , the film was acquired by the peter g . peterson foundation . you can watch it here .
exel limited adopts a mission statement detailing its strengths : capacity , stability , risk absorption and financial security .
gary scott , an original creator of the international investors club concept , replaces mark nestmann as financial editor .
through the publication of free and paid publications , we are able to provide unbiased market commentary and market news . agora financial is 100 % independent and our editors never accept money from companies or investors in exchange for coverage .
i know a doctor who lives in omaha , nebraska . he has made two financial fortunes in his lifetime .
newmarket group , an agora company , is in search of an enthusiastic and results - driven marketing associate . . . .
indeed , that’s where our name ‘agora’ is derived from… the name for the meeting place where ancient greeks would share ideas .
click on the link below to read the 16 - page agora publishing letter for their product ,
options hotline
.
a bronze statuette of eirene from the athenian agora , fifteenth international bronze congress , university of udine ( may 2001 ) .
but going forward , to create a clear sense of our work , we will be branding the products of both companies under the agora financial uk banner . we feel it acts as a better reminder of why we do what we do .
the name “agora” was initially decided upon for those half dozen writers in 1978 . the word is a greek term for marketplace .
starting in 1999 , agora financial hosted the annual investment symposium . held in vancouver , b . c . , the conference brought together a large number of speakers discussing emerging financial trends , as well as panels and debates . speakers at the event have included marc faber , doug casey , steve forbes and many others . the last symposium was held in 2013 .
not only have our economic forecasts been uncannily accurate , but we’ve consistently beat the mainstream financial media to the punch .
in his usual wry and witty way , your humble daily reckoning editor opened the eighth annual agora financial investment symposium by suggesting that most people — those not here in this room or reading this report in particular — are braver than they’ve ever been .
but the idea of the agora remained . eventually , it would become a foundation for other contrarians and entrepreneurs all around the world .
karim rahemtulla , research director of agora publishing , replaces chris weber as investment director and becomes editor of the oxford alert trading service .
the newsletter was steve sarnoff’s options hotline , published by a baltimore - based company known as agora financial , itself a subsidiary of a holding company also named agora , one of whose founders , the late gregory barnhill , was a protege and close associate of buzzy krongard . ( barnhill reportedly committed suicide in 2012 . ) the bank a . b . brown is also based in baltimore .
more recently , agora financial has promoted the writings of economist james rickards , who purports to be a financial adviser to the us intelligence community . in the first chapter of his 2014 book the death of money , rickards absurdly argues that al qaeda was responsible for the pre - 9 / 11 insider trading , an obvious and transparent attempt to divert attention from the actual insiders .
money map press , an agora company , is seeking a junior copywriter who is looking to advance and grow their career . . . .
robert williams , editorial director for the club , is promoted to publisher of the new wall street daily , an agora inc . affiliate .
the critically - acclaimed documentary film i . o . u . s . a . was concieved of , co - written and executive produced by agora financial ' s addison wiggin . in july 2008 , the film was acquired by the peter g . peterson foundation .
as coeditor of technology profits confidential and contributor to breakthrough technology alert and penny sleuth at agora financial , ray blanco searches far and wide for breakthrough ideas and disruptive technologies that will change the lives of very sick patients . in this exclusive interview with the life sciences report ,
robert williams , editorial director for the club , was promoted to publisher of the new white cap research group , an agora inc . affiliate .
along with the other 700 people here , i am going to attempt to be one of the first in line for a cocktail , compliments of our host , agora financial . so that we can get up and do it all again tomorrow . i hope you’ll join me .
julia guth , alexander green and the team started total financial solution meetings for new members of the chairman’s circle – all sold out .
alex green returns from a world financial tour to china . completely excited about the emerging opportunities there , he launches the new china trader
the oxford club’s investment advisory team takes actions to protect the club and its members from the the world financial crisis and market collapse .
2 ) i think publishing what i wrote for them in my newsletter will get agora some extra business . the letter describes an amazing financial service i think some of you will want to have . you need to remember though , my sales letter will not be used by agora until it is proofread and checked for accuracy . but i think as it stands now , it is 99 . 9 % ready to be mailed .
copyright © 2018 — the agora • all rights reserved . • 14 west mt . vernon place , baltimore , md 21201 , usa • privacy policy
xl capital assurance inc . establishes aaa rated , london - based financial guarantee subsidiary , xl capital assurance ( u . k . ) limited
alex green returned from a world financial tour to china . completely excited about the emerging opportunities there , he launched the new china trader .
julia guth , alexander green and the team start total financial solution meetings for new members of the chairman’s circle – and all sell out .
14 west is the business services arm of the agora companies , and has offices in baltimore city , maryland and delray beach , florida . . . .
health sense media , an agora company , is seeking a highly motivated media buyer to spearhead their customer acquisition strategy on the native and display . . .
the agora financial customer service department is open monday through friday , 9 a . m . - 5 p . m . est . please feel free to contact us , should you have any questions or concerns regarding your account , billing , navigating our website , product information or any related topic .
addison wiggin and bill bonner provide their readers with honest and unconventional insight . agora financial has been recognized by numerous media sources including the new york times , wall street journal , the economist , financial times , reuters , usa today , fox , abc , money , cbs , businessweek , us news & world report , washington post , chicago tribune , san francisco chronicle , los angeles times , and the daily telegraph to name but a few .
his career at agora , inc . – the world’s leading financial newsletter publisher – began in 1993 , when he was trained as a copywriter by industry legends bill bonner and michael masterson , ultimately earning the prestigious and coveted ouzilly award for writing excellence at a ceremony in ouzilly , france , in 2003 .
filled with in - depth insights and practical advice , financial reckoning day fallout warns that depressions are not necessarily a thing of the past . learn more
to receive the best in timely and topical thinking on economic and financial policy issues and events , sign up for this free e - letter here .
the oxford club partners with the money show and continues its tradition of providing first - class world financial cruises , this time through the panama canal .
independent newsletter rating service hulbert financial digest once again ranks the oxford communiqué in the top 10 in the country for its 10 - year track record .
disclaimer : any and all communications from agora financial llc employees should not be considered personalized investment advice . although our employees may answer your general customer service questions , they are not licensed under securities laws to address your particular investment situation . no communication by our employees to you should be deemed as personalized investment advice .
the club established a new oxford club library at the bonner’s château courtomer in france , near normandy ( urltoken ) . members are welcome to rent the entire château at a discount as part of our property exchange . the club’s world financial seminar team planned a financial retreat there in the summer of 2010 .
club members enjoy vip financial tours and cruises around the world , from munich and vienna to st . petersburg , canada , nicaragua , italy and southeast asia .
not somber , mind you . libations will flow . animated conversation will fill the halls . madmen , prophets and sages will entertain us . after all , it’s the eighth annual agora financial investment symposium . and we couldn’t fit another chair in the room if we wanted to . it would be impossible not to have a good time .
the 2013 agora financial investment symposium is rapidly approaching ! it will take place in beautiful vancouver , british columbia . this symposium will run from july 23rd until july 26th and is located at the fairmont hotel vancouver . some of the greats in the industry have been invited , including sprott ' s very own rick rule and david franklin .
today the name “agora” is synonymous with icons of the alternative press , and masters of direct marketing . the agora , as the group is now known , is a community for companies that were all born of the same vision and philosophy – companies that celebrate the virtue of thinking independently and taking individual responsibility for your health , wealth , and future .
and for those who fear that this upward trend in commodities could be about to turn down , longtime agora alum dan denning disagrees . and offers up history as his witness :
just type in
early to rise agora publishing
in your search engine and you ' ll find the link where you can sign up for this valuable and free information .
the film i . o . u . s . a . was inspired by the international best - sellers financial reckoning day and empire of debt , which mr . wiggin co - authored with william bonner in 2003 and 2005 , respectively . to the delight of many , both books were fully revised and released in the summer of 2009 . financial reckoning day fallout : the 10th anniversary edition is a timely guide to protecting and growing your wealth in this turbulent financial climate . casting a wide - angle lens through history , the second edition of t he new empire of debt depicts the rise — and fall — of our epic financial bubble .
in the ensuing 16 years , addison has been an avid student , writer and commentator on financial markets and governments . he spent a year in the fundraising and communications department at the cato institute in washington , d . c . , and several years living and traveling abroad —including a four year - stint in paris , where he worked side by side with bill bonner establishing agora’s french subsidiary , publications agora , and founding the u . s . and u . k . editions of the daily reckoning in london .
i think all of you know about agora publishing . they are one of the largest success stories in direct marketing . that ' s true for both on - line and off - line marketing . agora sends out very informative messages called
early to rise
and i think everybody who reads my newsletter should also be reading
early to rise
.
the new empire of debt reveals how the epic financial bubble that is plaguing the united states will soon bring an end to this once - great empire . learn more
pointedly topical and consummately nonpartisan , i . o . u . s . a . drives home the message that the only time for america’s financial future is now !
the uk edition launched a year later – in the heart of london , serving contrarian investment advice and a fresh look at the financial markets from a british perspective .
14 west , an agora company , is looking for an experienced recruiter to join its talent acquisition team . as a recruiter on our team , you’ll serve as a dedicated . . .
in the mid - ’80s scott turned it over to bill bonner , the ceo of agora , inc . in baltimore , md . , a global financial and travel publishing company . in 1989 bonner changed the name to the passport club and hired recent thunderbird mba graduate julia guth as membership director . her job was to expand the club’s services and local chapter participation .
we’ve gathered some of the world’s top financial analysts and commentators to share their proven wealth - building strategies with you . here are a few of our collected experts and their accolades .
the newsletter rating service hulbert financial digest rates the oxford communiqué one of the top newsletters in the industry , in the top five for its track record over the last three years .
i can’t package and send you some of the best parts of the conference . those are reserved for attendees . like the wine tasting with our favorite argentinean sommelier , andres rosberg — for agora financial reserve members only . or the private yacht that will escort us around the harbor and find the perfect view for the fireworks . or the sneak preview of our documentary - in - progress .
united states : the daily reckoning australia : the daily reckoning australia united kingdom : the daily reckoning | u . k . edition france : la chronique agora germany : investor verlag south africa : the weekly reckoning
as crimes go , this action against chevron makes the billions that bernie madoff stole look like peanuts . this case is doubtless among the largest financial crimes in history . background to the ecuador case
then again , $ 113 billion is a lot of money to try to steal . as i said above , this is one of the largest financial crimes in history , unfolding before us .
the club creates the pillar one program , a network of specialized and discounted services from the country’s leading financial and travel firms . julia establishes a $ 5 , 000 annual student scholarship program .
the club continues to take members around the world to seek out global investment opportunities with its world financial seminars and tours division , which includes tours to south africa , china , new zealand and australia .
having said all that , i now want you to know agora financial publishing in baltimore , maryland recently hired me to create a direct mail piece for a publication they have titled
options hotline
. i just finished that piece and delivered it to them yesterday . it ' s a 16 - page sales letter . and , when you are finished reading this newsletter , you can download it and read it for yourself .
two hours each way , i might add . i conclude , david walker for president and agora as his esteemed cabinet ! . . . the documentary was top - notch , i give it an a - . i can ' t say much more than it was very well produced and that the facts delivered were truly eye - opening — even for an agora faithful like myself . everyone needs to see this ! excellent movie — well worth the drive .
calling the shots is lead analyst dan amoss . he holds the chartered financial analyst® designation , a professional designation widely recognized within the investment community . and one of his first jobs was with investment counselors of maryland . . .
the club teams up with the new orleans investment conference to sponsor one of the country’s largest annual financial conferences . oxford club advisory panelists share the spotlight with john stossel , sir john templeton , barbara bush and milton friedman .
steven king of world financial seminars launches the club’s first two - day , high - end , intensive regional meetings for members who want in - depth instructional presentations from our advisory team about their investment strategies . the event in jackson hole immediately sells out .
jesse is currently director of new initiatives at agora partnerships , where he leads partnership building , fundraising efforts , and is a member of the entrepreneur recruitment team . before joining agora , jesse worked on a range of international development projects in east africa , was a political reporter for a newspaper in south carolina , and was the co - founder of a start - up focused on using social media to market emerging musicians in north carolina . he also worked in a small - business development project called africa b2b that distributed low - interest loans to companies in uganda .
sometimes , however , the bad guys use less violent means , such as by bringing baseless lawsuits and demanding large financial settlements . this kind of “lawfare” can severely harm companies , as well as add years of delay to development projects . thus , we need to understand what’s happening .
after that , i wrote a letter for a collection agency called financial adjustment service . this company was to be owned by me and two of my friends . alas , the company never got off the ground . but that early letter i wrote ( with no training whatsoever ) was a virtual masterpiece .
the oxford club’s investment advisory team battens down the hatches to protect the club and its members from the greatest crisis since 9 - 11 : the world financial crisis and market collapse . we stop out of every position in the communiqué’ s trading portfolio , but our closed - out positions still return an impressive 28 % .
recent developments are shocking . there’s a wide - ranging conspiracy of u . s . and ecuadorean lawyers , consultants and other players all working to fabricate a baseless — and astronomical — damage claim against chevron . the goal is to co - opt the ecuadorean legal system to impose a punishing financial verdict against an american company .
rickards ' s crypto profits is a one - of - a - kind newsletter taking an alternative approach to the cryptocurrency markets . rather than speculate , financial expert jim rickards and investment director greg robinson calculate which cryptos and blockchain companies can stand the test of time . sign up for the most exciting crypto plays each month .
concurrently in the mid - ’80s , an investment and business publisher in florida launched a financial newsletter called the oxford club . it grew to 10 , 000 readers worldwide . the publishing company sold its interest to bonner in 1991 . bonner welcomed these new members into his group and changed the name from the passport club to the oxford club because he thought the name evoked a spirit of tradition and old world charm . he charged julia with combining the best of the oxford club and the passport club and expanding on it . mark nestmann , an international wealth - protection and privacy expert , became financial editor of the monthly oxford club investment newsletter , the oxford communiqué .
in an interview , walker is full of grim one - liners , such as :
the debt has increased our risk of being held hostage by foreign lenders
and
our situation is serious , and it is deteriorating with the passage of time
and
the financial condition of the u . s . is worse than advertised .
we regularly write from the international financial capitals of london , hong kong , paris , singapore , and dubai . as well as from any locale where an important story can be found , be it argentina , brazil , cambodia , germany , egypt , india , south africa , nepal , nicaragua , thailand , vietnam , or any other country .
as such , he is credited by urltoken for “calling it first and calling it right” with respect to the current and ongoing global financial crisis . wiggin offers his analysis “with confidence and steady aplomb , ” says the new york times magazine , and offers “a clear , cogent and compelling primer on contemporary american economics , ” according to the toronto star .
our editors are not afraid to make bold predictions . their insights have been recognized the wall street journal , the economist , cnbc , fox business news , reuters , bloomberg , u . s . news & world report , financial times , the washington post , san francisco chronicle , rt , los angeles times , the daily telegraph and many more .
the demand for enough raw materials and energy to keep pace with growth throughout the pacific rim far outpaces supply . the stock market and financial markets in these countries are more volatile than most investors are prepared to handle . and then there’s the issue of food — the one resource that can’t be overlooked when such a mammoth population needs to be fed .
with surgical precision , creadon interweaves archival footage and economic data to paint a vivid and alarming profile of america’s current economic situation . the ultimate power of i . o . u . s . a . is that the film moves beyond doomsday rhetoric to proffer potential financial scenarios and propose solutions about how we can recreate a fiscally sound nation for future generations .
roger graduated with honors from thomas more university in managua , nicaragua with a degree in political science and international relations . he also holds a diploma in youth leadership . roger worked at the nicaraguan export and investment center where he witnessed the importance of helping small and medium enterprises to grow . he is now happy to be working with agora to support social entrepreneurs and accelerate positive impact in society .
cnn to broadcast i . o . u . s . a . the public has spoken , and we ' ve listened . in response to demand for information about our country ' s financial challenges , cnn / u . s . will air the broadcast premiere of the acclaimed documentary i . o . u . s . a . get the details > >
a bronze statuette from the athenian agora : a technical and iconographical examination , in i bronzi antichi : produzione e technologia . atti del xv congresso internazionale sui bronzi antichi , organizzato dall ' università di udine , sede di gorizia grado - aquileia , 22 - 26 maggio 2001 ( monograph instrumentum 21 ) , a . giumlia - mair , ed . montagnac , 2002 , pp . 167 - 173 .
cnn to broadcast stratham native ' s film jan . 10 - 11 in response to demand for information about the nation ' s financial challenges , cnn / u . s . will air the broadcast premiere of the acclaimed documentary
i . o . u . s . a . ,
co - written and executive produced by stratham native addison wiggin . get the details > >
throughout history , the american government has found it nearly impossible to spend only what has been raised through taxes . wielding candid interviews with both average american taxpayers and government officials , sundance veteran patrick creadon ( wordplay ) helps demystify the nation’s financial practices and policies . the film follows u . s . comptroller general david walker as he crisscrosses the country explaining america’s unsustainable fiscal policies to its citizens .
elysa brings a wide range of experience in marketing and communications . prior to joining agora , elysa worked in communications at a political and corporate consulting firm and served as media director for a fair wage start - up committed to empowering guatemalan communities . elysa holds a ba in international area studies with a focus in sustainable development from washington university in st . louis . in her free time , she enjoys travel , hiking , and painting .
in the early years , agora was a publisher that had set out to share original , alternative , and useful views . it was the world’s first open source marketplace for ideas . “sometimes right , sometimes wrong , and always in doubt , ” was their motto . they did not claim to have the last word on every issue , but believed that readers ought to be offered different perspectives . from there they could make up their own minds .
from 1993 to 2017 , regula wallimann worked for kpmg switzerland , where she acted during 14 years as global lead partner for various large listed and non - listed international and national clients . she has been advising clients in the fields of corporate governance , risk management , compliance , financial reporting , consolidation and process optimization . from 2012 to 2014 , regula wallimann was member of kpmg switzerland’s strategic partners ' committee .
i want you to stop reading my newsletter here . . . and instead . . . download and read the sales letter for agora . it ' s very important you do it in this order . you see , after you ' ve downloaded and read that letter , you need to come back to my website and continue reading this newsletter . that ' s because i want to give you some more information and ask you a few crucial questions .
computer technology has also introduced a new level of anonymity , in the form of faceless transactions that do not require the intermediation of a financial institution . internet money transfers and new payment technologies such as “e - cash , ” electronic purses and other electronic payment systems have created new ways to disguise the source and ownership of illicit money , as discussed in a us treasury report of september 2001 on money laundering . xxi
by searching for encryption keys , indicating a financial record , convar found evidence stored on the drives of an “unexplained surge” in large credit card transactions prior to the attacks . according to reuters : “unusually large sums of money , perhaps more than $ 100 million , were rushed through the computers as the disaster unfolded . ” evidently , the criminals wrongly assumed that it would be impossible to trace their transactions after the computers were destroyed .
a board of governors was formed and james boxley cooke was named honorary chairman . cooke , a recently retired investment advisor from t . rowe price , became the primary spokesperson for the club throughout the ’90s . the club’s “bible , ” the traditions of wealth , was published and offered to all lifetime members . gary scott , an original creator of the international investors’ club concept , replaced mark nestmann as the financial editor for the oxford club .
the newsletter rating service hulbert financial digest rated the oxford communiqué one of the top newsletters in the industry , in the top 5 for its track record over the last three years . alex green introduced two new “fund - oriented” portfolios to the communiqué that employ different exit strategies than trailing stops : the all - star portfolio and the gone fishin portfolio . the gone fishin’ portfolio introduced the nobel prize - winning strategy of asset allocating as well as using annual “rebalancing” to members .
ok , before you download and read the sales letter i told you about , you should know i am working on this project with a guy who works for agora whose name is greg . he seems to be a savvy and a guy easy to work with . before you read the sales letter i sent to him , i ' d like you to read the cover letter about this project which i also sent to him . i sent it by both fax and email . here ' s my cover letter to greg :
wiggin is the founder of agora entertainment , and executive producer and co - writer of the highly acclaimed documentary film i . o . u . s . a . , which was nominated for the grand jury prize at the 2008 sundance film festival and the 2009 critics choice award for best documentary feature and was also shortlisted for a 2009 academy award . he is the author of the companion book of the film i . o . u . s . a . and a three - time new york times best - selling author .
before joining agora , anne was manager in strategy in deloitte méxico . prior to this , she worked in corporate finance in pwc . she is passionate about social consulting since she co - founded 2 social consulting organizations in france and in mexico . she holds a master in corporate finance and strategy from sciences po strasbourg in france , and studied the executive program in social impact strategy at the university of pennsylvania . for fun , anne loves traveling the world , debating with her friends about everything , reading historical books and she adores her mexican cat named “frida”
what you should do ( once again , if you can afford it ) is hire me while the
getting ' s good
. i have a sneaking suspicion this door won ' t be open for very long . for one thing , i think after agora tests the letter you downloaded and read , they are going to want to
own
me . well , nobody ' s ever going to own me . ( except sirian , of course . ) but if the price is right , i will be available for an
exclusive lease
.
x the list included six airline stocks : american , united , continental , northwest , southwest and us airways , as well as martin , boeing , lockheed martin corp . , aig , american express corp , american international group , amr corporation , axa sa , bank of america corp , bank of new york corp , bank one corp , cigna group , cna financial , carnival corp , chubb group , john hancock financial services , hercules inc , l - 3 communications holdings , inc . , ltv corporation , marsh & mclennan cos . inc . , metlife , progressive corp . , general motors , raytheon , w . r . grace , royal caribbean cruises , ltd . , lone star technologies , american express , the citigroup inc . , royal & sun alliance , lehman brothers holdings , inc . , vornado reality trust , morgan stanley , dean witter & co . , xl capital ltd . , and bear stearns ; “bank of america among 38 stocks in sec ' s attack probe , ” bloomberg news , october 3 , 2001 , see note 7 .
the securities and exchange commission led the us government probe of allegations of insider trading . ix for weeks , the sec remained close - mouthed about the scope of its investigation ; then it sent out a request to securities firms around the world for more information on trading in thirty - eight different stocks . x sec chairman harvey pitt told the house financial services committee , “we will do everything in our power to track those people down and bring them to justice . ” xi by this time , however , the fix was apparently in .
the suspicion is that insider information about the attack was used to send financial transaction commands and authorizations in the belief that amidst all the chaos the criminals would have , at the very least , a good head start … of course , it’s possible that americans went on an absolute shopping binge , that tuesday morning . but at this point there are many transactions that cannot be accounted for . not only the volume but the size of the transactions was far higher than usual for a day like that . there is a suspicion that these were possibly planned to take advantage of the chaos . xliii
dr . mark skousen replaced dr . steve sjuggerud as chairman of investment u . investment u raised over $ 130 , 000 in relief funds for hurricane disasters . horacio marquez launched the new money map trader . the oxford club launched its first online gift merchandise store ( urltoken ) . the communiqué’ s trading portfolio under alex green and lou basenese finished the year with 100 % profitability… all positions in the black… and mightily beat the s & p again . colleen monahan joined the oxford club as head of operations . world financial seminars launched one of its first wealth cruises , this year to alaska .
hans ploos van amstel started his career in finance at procter & gamble ( p & g ) in the netherlands in 1989 . between 1992 and 2003 , he held positions of increasing responsibility in p & g across saudi arabia , germany , belgium and switzerland . in 2003 , he joined levi strauss & co . in belgium , as vice president finance & operation europe , and moved to the usa as global chief financial officer in 2005 . in his most recent position , hans ploos van amstel was cfo of cofra group from 2009 to 2013 , before acting as co - ceo of c & a europe for a transition period until 2015 .
the club grew to over 36 , 000 members in over 100 countries , and offered its members many new benefits , including access to an in - house research staff and a member service staff – all employed at the club’s new mansion in the historic district of mt . vernon in downtown baltimore ( “the clubhouse” ) . it also established local publishing offices in london and bonn ( under the name of the zurich club ) and paris . karim rahemtulla , research director of agora publishing , replaced chris as investment director and became editor of the oxford alert trading service . by the end of 1996 , the oxford communiqué was published in three different languages : english , french and german , all still sent by mail only .
maria was born and raised in nicaragua in a family of entrepreneurs where she witnessed first hand the endless potential of a well - run business . while pursuing her mba at hult international business school in san francisco she had the opportunity to work in strategic projects with high tech startups and venture capitalist partners , experiencing both the passion and pragmatism that every new business must strive to balance if it is to be successful . prior to her mba , she worked as a financial auditor at pwc nicaragua and pwc panama . she has a bs in accounting and marketing . in her free time she likes to dance , do yoga , learn new languages , and experience new cultures .
we’ve invited one of the more observant — and , well , nosy — financial writers we know to be your eyes and ears on the scene . her name is monica day . not only will she be anchored in the back of the room jotting down as much as she can of what is said during the conference… but we find that we see her out and about until all hours , discussing the ideas of the day with our editors and attendees . yet she seems to remain sober enough to recall the details when writing her reports . remarkable . if anyone can give you the inside scoop , we’re sure monica can . you’ll get her daily reports delivered right to your inbox every day of the conference , starting tomorrow .
laissez - faire is a french term meaning “let them be . ” it refers to the belief that an individual is best equipped to solve their own problems and create a more prosperous society , while bureaucratic mandates and top - down control tend to make problems worse .
true to that tradition , our goal is to help you learn the laissez faire philosophy from some of the best philosophers , academics and advocates of liberty who ever lived — and show you how to apply this idea with actionable strategies and tips on getting government out of your life .
laissez faire books started in 1972 when founders john muller and sharon presley opened a little libertarian bookstore in greenwich village . the official opening was attended by many local libertarian writers , including murray rothbard , roy a . childs , jr . and jerome tuccille .
the store sold libertarian , political philosophy and anti - authority thought from murray rothbard , ludwig von mises , albert jay nock , alexander berkman and peter kropotkin , as well as anarchists lysander spooner and karl hess .
as the years passed , laissez faire books changed locations and ownership , but the independent ideals at its core never wavered .
from a brick - and - mortar bookstore business in the ’70s to an online web - focused business in the 2000s .
still to this day , the ideals set forth in 1972 by the founders of the little bookstore are defended voraciously .
in august 2013 , the laissez faire letter was launched . true to its roots , this monthly newsletter attracts individuals willing to take action to live a more independent and self - reliant life .
this version of the business evolved once again to meet the changing needs of its readers , providing actionable solutions to overreaching government and its cozy relationship with big wall street banks and other industries .
the laissez faire letter includes a four - page monthly feature called unconventional wealth , a unique , practical , step - by - step guide on wealth creation . it teaches readers novel ways to grow and protect their wealth , so they’re safe no matter what happens on wall street .
today , the laissez faire family has expanded to include jason hanson’s spy & survival briefing . as a former cia officer , jason’s mission is to provide readers with the knowledge , skills and products to protect themselves and their family in the face of danger , economic turmoil , natural disasters and more .
in every newsletter , the business finds an opportunity to spread the ideas that are important to us . although these ideas may seem varied , each of our newsletters is designed to bring freedom , reliance and self - sufficiency into every sphere of your life .
although we no longer have a book store , our founders’ ideals are present in every newsletter we publish .
and as the laissez faire family continues to grow , we are committed to ensuring this remains true .
a private - equity billionaire , a former federal government official and a baltimore newsletter editor have made a documentary film that they hope can do what an endless parade of policy papers has not : persuade americans that debt has created a looming economic crisis that would make the great depression look like a market correction .
the movie ,
i . o . u . s . a . ,
debuting aug . 21 , is an 87 - minute alarum on what it calls the tsunami of debt bearing down on the united states ' future , caused by the rising national deficit , the trade imbalance and the pending costs of baby boomers cashing in on entitlements .
early reviewers have dubbed the film
an inconvenient truth
for the economy , meaning it ' s not exactly the feel - good movie of late summer 2008 .
except for budget wonks in love , it hardly counts as a date movie . the film ' s thrilling action sequence has a guy going to a refrigerator for a tab . there are no car chases and nothing blows up .
in march of this year , walker resigned from the gao so he could be even more vocal on the debt crisis , becoming chief executive of the newly formed peter g . peterson foundation , set up by peterson , billionaire co - founder of the blackstone group , a major private - equity player .
their message : you probably know that the national deficit is $ 9 . 6 trillion and rising . what you don ' t know is how bad things really are . if you include all the unfunded entitlement obligations - - social security , medicare , medicaid and so forth - - we are actually in a $ 53 trillion hole , walker says .


santaris pharma a/s is a biopharmaceutical company founded in 2003 in copenhagen , denmark with a small branch in san diego , california that opened in 2009 .

created by a merger between cureon and pantheco , santaris pharma a/s has become a leading clinical-stage biopharmaceutical company that develops rna-targeted medicines using a locked nucleic acid ( lna ) drug platform and drug development engine .

the company was acquired by roche in august 2014 .

santaris has the worldwide exclusive intellectual property rights to the therapeutic applications of locked nucleic acid ( lna ) technology .

this includes ownership of over 60 patent types , which range from the chemistry to manufacturing and from therapeutic uses to drug design .

with their lna technology , santaris works on developing drugs for a wide range of diseases using microrna and mrna .

their research focuses on infectious disease and metabolic disorders .

they also work on collaborations with pharmaceuticals to develop drugs for rare genetic disorders , cancers , cardiovascular disease , and immune and inflammatory diseases .

santaris pharma

2 santaris pharma , kogle allé 6 , dk - 2970 hørsholm , denmark .
in 2010 , exiqon initiated arbitration proceedings to defend its business against santaris pharma .
said søren tulstrup , president and chief executive officer , santaris pharma a / s .
isis pharmaceuticals , inc . v . santaris pharma a / s corp . et al
bristol - myers squibb is teaming up with santaris pharma to discover and develop novel medicines using santaris pharma ' s locked nucleic acid ( lna ) drug platform . santaris pharma is a biopharmaceutical company focused on developing medicines targeted to disease - related mrnas and micrornas .
for access to santaris pharma a / s lna technology for the development of rna - targeted drugs . santaris pharma a / s is eligible to receive milestone payments of up to
between santaris pharma a / s and wyeth , which was acquired by pfizer inc . under the terms of the original collaboration , santaris pharma a / s received an upfront payment of
said henrik ørum , vice president and chief scientific officer at santaris pharma a / s .
santaris pharma – according to an aug 4 , 2014 press release , roche announced that it has agreed to acquire santaris pharma based near copenhagen , denmark . santaris pharma has pioneered its proprietary locked nucleic acid ( lna ) platform that has contributed to an emerging era of rna - targeting therapeutics .
santaris pharma owns the worldwide exclusive rights to develop innovative new drugs based on lna technology . santaris pharma and h . lundbeck will collaborate on the development of potential neurological drugs arising from the platform .
j . donald debethizy , president and ceo of santaris pharma , said , “roche and santaris pharma have complementary capabilities… the acquisition combines santaris pharma’s next - generation antisense technology and lna expertise with roche’s deep experience in disease biology , chemistry , drug safety , drug formulation , delivery , and development . ”
santaris pharma is a danish clinical stage biopharmaceutical company . the company was formed in 2003 and has the exclusive rights to lna technology , used to develop new classes of rna medicines , called rna antagonists . santaris pharma
“roche and santaris pharma have complementary capabilities that will help us realize breakthrough medicines , ” stated j . donald debethizy , president and ceo of santaris pharma . “the acquisition combines santaris pharma’s next - generation antisense technology and lna expertise with roche’s deep experience in disease biology , chemistry , drug safety , drug formulation , delivery , and development . ”
santaris pharma a / s announces expanded worldwide strategic alliance with pfizer inc . directed to development of rna - targeted med
santaris pharma a / s announces expanded worldwide strategic alliance with pfizer inc . directed to development of rna - targeted medicines
santaris pharma is a danish clinical stage biopharmaceutical company . the company was formed in 2003 and has the exclusive rights to lna technology , a 3rd generation antisense chemistry used to develop new classes of rna medicines , called rna antagonists . santaris pharma
santaris pharma a / s uses its proprietary locked nucleic acid ( lna ) platform and tissue - targeting expertise to pioneer next - generation antisense product candidates . santaris pharma is developing a diverse pipeline of lna therapeutics that influence the production or activity of select rna targets to address diseases that are difficult - to - treat with conventional drug modalities . santaris pharma’s innovation and leadership position has attracted multiple collaborations with leading global pharmaceutical companies . founded in 2003 , santaris pharma is headquartered in denmark .
wyeth pharmaceuticals is continuing efforts to improve its capabilities in the formulation and delivery of rna through a strategic partnership with santaris pharma .
since gilde invested in santaris pharma , the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with glaxosmithkline , pfizer , bristol - myers squibb , roche and shire . santaris pharma was acquired by roche in 2014 for $ 450m .
santaris pharma randi krogsgaard , + 45 4517 9879 director , corporate communications cell : + 45 20488384 rmk @ urltoken www . urltoken
santaris pharma a / s announces expanded worldwide strategic alliance with pfizer inc . directed to development of rna - targeted med | fiercepharma
rana therapeutics , inc . and santaris pharma a / s announce agreement to develop rna - targeted medicines that selectively activate protein expression
exiqon had requested that santaris pharma be ordered to pay damages . however , the arbitration court did not find grounds for damages .
the award is the first program grant to be made by the atf and is the third and largest award from the danish atf to a santaris pharma led collaborative group . the three year program will enable santaris pharma to identify 3 - 5 new rna drug candidates . in 2006 and 2007 the atf made two separate project grants to santaris pharma and the university of copenhagen totaling approximately dkk 20m (
santaris pharma a / s announces expanded worldwide strategic alliance with pfizer inc . directed to development of rna - targeted medicines | mirna blog
we would like to thank our colleagues at santaris pharma and all our collaborators who have contributed to the miravirsen endeavor over the years .
equity investment in santaris pharma a / s . santaris pharma a / s continues to be eligible to receive milestones and royalties under the original alliance . pfizer has advanced several programs under the original collaboration and reached a number of early milestones since the inception of the collaboration .
roche announced that it has agreed to acquire santaris pharma . santaris pharma has pioneered its proprietary locked nucleic acid ( lna ) platform that has contributed to an emerging era of rna - targeting therapeutics . this new class of medicines has the potential to address difficult to treat . . .
as the leader in developing lna - based drugs , santaris pharma a / s is very pleased that the uspto has ruled in favor of santaris pharma a / s and upheld the company ' s ' imanishi ' patents ,
said soeren tulstrup , president and ceo of santaris pharma a / s .
the uspto rulings affirm the strong intellectual property position of santaris pharma a / s as it continues to develop effective rna - targeted therapies with high affinity , target specificity and remarkable potency for a range of diseases both internally and with its partners .
santaris pharma a / s announced it has established operations in the united states . increasing interest , new collaborations and breakthrough advancements utilizing the company ' s proprietary rna - based locked nucleic acid ( lna ) drug platform and drug discovery engine led santaris pharma a / s to . . .
roche announced that it has agreed to acquire santaris pharma . santaris pharma has pioneered its proprietary locked nucleic acid ( lna ) platform that has contributed to an emerging era of rna - targeting therapeutics . this new class of medicines has the potential to address difficult to treat . . . more
exiqon a / s ( nasdaq omx copenhagen : “exq” ) today announced that the company has completed its litigation against santaris pharma a / s .
a drug for hepatitis c virus from santaris pharma shows effectiveness in reducing the potentially deadly virus in people , according to new clinical trial results .
santaris pharma a / s announced it has established operations in the united states . increasing interest , new collaborations and breakthrough advancements utilizing the company ' s proprietary rna - based locked nucleic acid ( lna ) drug platform and drug discovery engine led santaris pharma a / s to . . . more
roche ' s return to the field of rnai research looks to be complete , following its $ 450m deal to acquire denmark ' s santaris pharma .
denmark - based santaris pharma a / s appoints leading rna industry expert art levin ph . d . as president of us operations and chief development officer
, phd , vice president and chief scientific officer of santaris pharma a / s .
santaris pharma a / s has dedicated its scientific know - how and expertise to advance lna - based chemistries into a versatile lna drug platform for the development of new rna - targeted drugs for human diseases .
roche announced that it will acquire santaris pharma , a private clinical stage biopharmaceutical firm focused on rna - targeted therapies , for up to $ 450 million .
santaris pharma will receive an up - front payment of $ 10 million , up to $ 90 million in potential milestone payments per product , and funding of ongoing discovery and research activities . in addition , santaris pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance .
6m , $ 9m ) towards the development of a high - throughput drug discovery platform for novel rna medicines . the project will be based on santaris pharma
during proceedings , santaris pharma submitted a counter claim against exiqon for damages in the amount of dkk 100 million . this claim was dismissed on substantive grounds .
hørsholm , denmark / san diego , california , january 09 , 2014 —santaris pharma a / s , a privately held biopharmaceutical company , announced today that they have signed a worldwide strategic alliance with roche to discover and develop novel rna targeted medicines using santaris pharma ' s proprietary locked nucleic acid ( lna ) drug platform .
roche has renewed its interest in gene silencing drugs , paying $ 250m ( €187m ) for santaris pharma including its ‘antisense’ locked nucleic acid ( lna ) platform .
“we are pleased that dr . levin has joined our management team to establish operations in the us and oversee global development programs for santaris pharma a / s , ”
the arbitration court also decided on the distribution of the costs of proceedings . santaris pharma was awarded partial costs of dkk 2 million payable by exiqon within 14 days .
roche plans to maintain santaris pharma’s operations in denmark , where the existing site will be renamed roche innovation center copenhagen . under the terms of the agreement , roche will make an upfront cash payment of $ 250 million to santaris pharma shareholders and make additional contingent payments of up to $ 200 million based on the achievement of certain predetermined milestones .
following today’s decision , it is clear that both exiqon and santaris pharma may supply lna™ products for the research and development of pharmaceutical products containing lna™ as the active ingredient .
santaris pharma discovers and develops rna - targeted therapies to treat infectious diseases and metabolic disorders . through its partnerships with pharmaceutical companies , santaris covers a range of therapeutic areas including cancer , cardiovascular disease , infectious and inflammatory diseases , and rare genetic disorders .
roche said it will retain santaris’ operations in denmark under the new name roche innovation center copenhagen . the acquisition of santaris is expected to be completed this month .
the second edition in our pharma social media series , the uk twitter ranking . . . .
neither santaris nor isis commented on the dispute for this article , citing ongoing litigation .
formed in 2003 , santaris has not been short of big pharma interest in its technology , having sealed deals with companies such as bristol - myers squibb , glaxosmithkline , pfizer and shire .
navjot rai santaris pharma a / s , usa office : + 1 858 764 7066 ( ext . 206 ) cell : + 1 619 723 5450 e - mail : nra @ urltoken
that history includes a patent dispute between santaris and isis , generally acknowledged as the pioneer behind antisense drugs . isis sued santaris in august 2011 over patent infringement claims . the u . s . patent and trademark office ruled in favor of santaris in november 2011 .
s messengerrna antagonists and microrna antagonists are being developed to silence mrnas and micrornas associated with various diseases , including cancer , metabolic disorders and viral infections . santaris pharma completed a euro 40m second round of equity financing in may 2006 and a euro 20m third round of equity financing in december 2007 . santaris pharma has a global alliance with enzon pharmaceuticals of new jersey to develop and co - commercialise a series of santaris pharma rna antagonists for the treatment of cancer and a worldwide strategic alliance with glaxosmithkline for the discovery , development and commercialization of novel medicines against viral diseases .
the acquisition , which is subject to customary closing conditions , is expected to close in august 2014 . roche plans to maintain santaris pharma’s operations in denmark , where the existing site will be renamed roche innovation center copenhagen . under the terms of the agreement , roche will make an upfront cash payment of usd 250 million to santaris pharma shareholders and make additional contingent payments of up to
the deal will see wyeth select rna targets that santaris will develop drug candidates for using its lna platform , with the pharma major responsible for the development and commercialisation of products arising from the alliance .
under the terms of the agreement , santaris pharma and roche will collaborate on the discovery of lna drugs against a multitude of targets across several disease areas . roche will be responsible for the subsequent development and commercialization of products arising from the alliance . santaris pharma will receive an upfront payment of $ 10 million in cash , up to $ 138m in potential pre - clinical , clinical , regulatory and sales milestones per product , and funding of ongoing discovery and research activities . in addition , santaris pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance .
ep vantage brings a fresh view on pharma and biotech with incisive daily analysis , powered by evaluate ltd .
/ prnewswire / - - santaris pharma a / s , a clinical - stage biopharmaceutical company focused on the research and development of mrna and microrna targeted therapies , and pfizer inc . ( nyse : pfe ) , today announced that the companies have expanded their collaboration directed to the development and commercialization of rna - targeted medicines using santaris pharma a / s locked nucleic acid ( lna ) drug platform .
the santaris pharma a / s lna drug platform is the only rna technology with both mrna and microrna targeted drugs in clinical trials , demonstrating the broad utility of the proprietary platform . the unique combination of small size and high affinity achievable with santaris pharma a / s lna technology allows lna - based drugs to potently and specifically inhibit rna targets in different tissues without the need for complex delivery vehicles .
roche has agreed to acquire santaris pharma , a pioneer in the emerging era of rna - targeting therapeutics via its proprietary locked nucleic acid ( lna ) platform . the acquisition , which is subject to customary closing conditions , is expected to close in august 2014 . roche plans to maintain santaris pharma’s operations in denmark , where the existing site will be renamed roche innovation center copenhagen . under the terms of the agreement , roche will make an upfront cash payment of usd 250 million to santaris pharma shareholders and make additional contingent payments of up to usd 200 million based on the achievement of certain predetermined milestones .
law360 , los angeles ( february 27 , 2014 , 8 : 24 pm est ) - - a california federal judge on thursday refused to let santaris pharma a / s corp . off the hook in isis pharmaceuticals inc . ' s infringement suit accusing santaris of leveraging isis ' patented drug discovery development platform to sign multimillion - dollar development deals , saying santaris isn’t protected by a safe harbor statute .
we are delighted that isarna therapeutics selected santaris pharma as its partner , further validating that our lna drug platform is the technology - of - choice for developing rna - targeted medicines ,
said dr .
roche ( six : ro , rog ; otcqx : rhhby ) announced today that it has agreed to acquire santaris pharma , a privately held biopharmaceutical company based near copenhagen , denmark . santaris pharma has pioneered its proprietary locked nucleic acid ( lna ) platform that has contributed to an emerging era of rna - targeting therapeutics . this new class of medicines has the potential to address difficult to treat diseases in a range of therapeutic areas .
, chief scientific officer and vp business development of santaris pharma .
this deal is yet another example of our intention to add more alliances with biotechnology companies such as isarna therapeutics to our growing list of partners .
the acquisition , which is subject to customary closing conditions , is expected to close in august 2014 . roche plans to maintain santaris pharma’s operations in denmark , where the existing site will be renamed roche innovation center copenhagen .
new york , may 1 ( genomeweb news ) - danish drug developer santaris pharma said today that it has created a microrna research consortium in partnership with the department for medical biochemistry and genetics at the university of copenhagen .
santaris pharma a / s has substantial intellectual property rights that includes ownership of more than 60 patent families which cover the lna chemistry , manufacturing , therapeutic uses in patients and animals and optimal drug designs and drug formats .
miragen is using santaris ' lna technology to develop mirna - targeted therapies . miragen has a deal with
to spearhead the us expansion , santaris pharma a / s has appointed leading rna industry expert arthur a . levin , phd , as president of its us operations . in addition , dr . levin will hold global responsibility as vice president and chief development officer of santaris pharma a / s . dr . levin has 15 years of experience in rna - based research and more than 25 years of experience in the pharmaceutical industry . prior to joining santaris pharma a / s , dr . levin was senior vice president of drug development at isis pharmaceuticals where he was instrumental in advancing more than a dozen rna - based antisense drugs from basic research to clinical development .
announcing the alliance , president and ceo of santaris pharma , dr . don debethizy , said :
we are delighted that roche has deepened its commitment to the field of oligonucleotide therapeutics and we are obviously proud and honored that they have chosen santaris as their partner . this is a very important deal to santaris and we look forward to working closely with the roche teams in our joint pursuit of novel , breakthrough drugs .
santaris pharma is a clinical - stage biopharmaceutical company focused on developing a new class of drugs intended to switch off the expression of harmful genes . called rna antagonists , these new drugs are being developed by santaris and its corporate partners for the treatment of cancer and metabolic disorders . created in may 2003 and backed by a broad group of leading international life science venture capital investors , santaris pharma completed a euro 40m second round of equity financing in may 2006 . in july 2006 , the company entered into a global partnership with enzon pharmaceuticals of new jersey to co - develop and commercialise a series of santaris rna antagonists for improving the treatment of cancer .
the expansion of our collaboration with santaris pharma a / s demonstrates our strategic intention to partner with innovative biopharm / biotech companies to explore novel drug design technologies as a potential source for breakthrough therapeutics ,
said mikael dolsten , president of worldwide research and development at pfizer .
we have been encouraged by the progress of our oligonucleotide collaboration with santaris pharma and are eager to explore this expanded partnership for potential additional lna - based drug projects .
hoersholm , denmark and san diego , jan . 4 , 2011 / prnewswire / — santaris pharma a / s , a clinical - stage biopharmaceutical company focused on the research and development of mrna and microrna targeted therapies , and pfizer inc . ( nyse : pfe ) , today announced that the companies have expanded their collaboration directed to the development and commercialization of rna - targeted medicines using santaris pharma a / s locked nucleic acid ( lna ) drug platform .
the expansion of our collaboration with santaris pharma a / s demonstrates our strategic intention to partner with innovative biopharm / biotech companies to explore novel drug design technologies as a potential source for breakthrough therapeutics ,
said mikael dolsten , president of worldwide research and development at pfizer . he added ,
we have been encouraged by the progress of our oligonucleotide collaboration with santaris pharma and are eager to explore this expanded partnership for potential additional lna - based drug projects .
according to maraganore , “in the 2005–2009 period , big pharma made big bets on rnai technology platforms . unfortunately , some of the big pharma technology efforts have not been so successful , at least as measured by ind filings , of which there are none . ”
he added , “the santaris investment story exemplifies forbion’s ability to select new potential disruptive platform technologies at an early stage , which drive a clear medical break - through . this deal for santaris further extends forbion’s solid track record . ”
santaris pharma a / s is a privately - held biopharmaceutical company focused on developing rna - based drugs targeted to disease - related mrnas and micrornas . utilizing the company’s proprietary locked nucleic acid ( lna ) drug platform and drug discovery engine , santaris pharma a / s provides fast and efficient generation of lead lna drug candidates . the company’s own research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer , rare genetic disorders and inflammatory diseases . santaris pharma a / s , founded in 2003 , is headquartered in denmark with operations in the us . the company has strategic partnerships with enzon pharmaceuticals , glaxosmithkline , wyeth pharmaceuticals and shire plc . please visit urltoken for more information .
international biopharmaceutical company focused on the discovery and development of rna - targeted therapies for a range of diseases including metabolic disorders , infectious and inflammatory diseases , cancer and rare genetic disorders . ( prnewsfoto / santaris pharma a / s ) ( prnewsfoto / )
ørum declined to say how much money his company was spending to license the drug from roche . the tavistock group did not respond to a request for comment . ørum was a longtime executive at santaris pharma , which was acquired by roche in 2014 .
unlike isis’ more recent big pharma deals with j & j , gsk , biogenidec , and astrazeneca , however , i expect this to involve less early development work by isis as some of this would be the obvious job of the former santaris crew .
roche completed its acquisition of partner santaris for $ 250 million in cash up front and up to $ 200 million in undisclosed milestones . in january , santaris and roche partnered to discover and develop rna - targeted drugs against . . .
roche will acquire partner santaris for $ 250 million in cash up front and up to $ 200 million in undisclosed milestones . santaris is using its locked nucleic acid ( lna ) platform to develop antisense drug candidates . lead . . .
“forbion recognized that santaris’ lna chemistries were the best in class antisense technology when the firm led the recapitalization of the company in 2006 , ” said martien van osch , managing partner at forbion and board member of santaris pharma . “forbion has been a strong proponent of the company ever since , working closely with the management to promote the significant therapeutic potential of this new class of drugs .
increasing interest , new collaborations and breakthrough advancements utilizing the company’s proprietary rna - based locked nucleic acid ( lna ) drug platform and drug discovery engine led santaris pharma a / s , headquartered in denmark , to establish us - based operations in san diego , california .
in 2011 , the swiss pharma giant sold its rna interference ( rnai ) pipeline , delivery technologies and research facility to arrowhead research corporation exiting .
santaris will receive an upfront payment and is eligible for development , regulatory and sales milestones . furthermore , santaris will receive a share of any sub - licensing revenues and royalties on worldwide sales of alliance products . no further financial details have been disclosed .
to wit , in 2011 isis sued santaris for infringing its rnaseh gapmer patents by santaris signing on big pharma partners regarding rnaseh therapeutics development . isis viewed this as a form of monetizing their ip and consequently sued . if decided in isis’ favor , the case would have been a notable departure from the long - held practice of shielding preclinical business and drug development under the safe harbor of the research exemption .
/ prnewswire / - - santaris pharma a / s and betaisarna therapeutics gmbh announced today that they have signed an agreement whereby isarna gains access to santaris ' locked nucleic acid ( lna ) technology to further develop its next generation oligonucleotide product candidates . under the terms of the agreement , isarna obtains rights to utilize santaris pharma ' s proprietary lna drug platform to discover , develop and commercialize immunotherapeutics targeted against the cytokine transforming growth factor beta1 , beta2 and beta3 ( tgf - beta ) . tgf - beta represents a critical pathway in oncology as its overexpression has been linked to progression and poor patient outcomes for various cancers and is suspected to play a role in other diseases as well .
we are confident that the unique features of the lna drug platform can achieve clinical breakthroughs and look forward to working closely with the bristol - myers squibb team ,
henrik oerum , ph . d . , santaris pharma ' s cso and vp , business development commented .
roche innovation center copenhagen a / s is the home of rna therapeutics research ( rtr ) for roche pharma research and early development ( pred ) .
“pharma is becoming more modality agnostic instead of just summarily dismissing oligos as drugs . they are primarily now just looking at these agents as drugs . ”
over the now several decades–long history of nucleic acid therapeutics , big pharma has had an on - again , off - again relationship with the technology .
in october of this year , merck said it was restructuring r & d . the pharma did not say whether cuts will include its rnai platform .
/ prnewswire / - - santaris pharma a / s and rana therapeutics , inc . announced today that they have signed an agreement whereby rana gains access to santaris ' locked nucleic acid ( lna ) technology to develop rna - targeted medicines . under the terms of the agreement , santaris will license its proprietary locked nucleic acid drug technology to rana for the development of lna - based drug candidates against up to 10 rana proprietary rna targets . the license granted by santaris includes access to proprietary chemistry capable of delivering potent single - stranded lna - based drug compounds . rana will apply the lna chemistry along with its proprietary technologies for selective protein activation to develop rna - targeted medicines . santaris will receive an upfront payment and is eligible for target nomination payments , development milestones and royalties on each product .
santaris pharma a / s recently achieved a breakthrough in medical science as the first company to advance a microrna - targeted therapy into human clinical trials . a single - dose phase 1 trial in healthy volunteers has now been completed and an additional phase 1 multiple ascending - dose study is planned . the drug spc3649 specifically targets microrna - 122 ( mir - 122 ) , a host factor for hepatitis c virus replication . in 2008 , santaris pharma a / s published the results of successful microrna silencing with spc3649 in non - human primates in nature [ 1 ] .
new york ( genomeweb ) — isis pharmaceuticals and santaris pharma are currently negotiating a settlement to their roughly three - year - old patent - infringement lawsuit and believe there is
strong potential to settle
the litigation instead of going to trial , according to court documents filed this month .
wyeth has made an upfront payment of $ 7m in cash and a $ 10m equity investment in santaris . a further $ 83m may be paid in milestone payments for each of 10 potential targets . santaris will also receive worldwide royalties from products that reach the market .
last month , santaris pharma a / s announced a multi - year worldwide strategic alliance with shire plc to discover and develop new rna - based medicines to treat rare genetic disorders utilizing santaris pharma’s proprietary lna drug platform . this collaboration adds to the growing list of mrna and microrna drug discovery and development partnerships , which includes wyeth ( delivery of lead candidates against up to ten targets ) , glaxosmithkline ( four viral disease drug candidates ) and enzon pharmaceuticals ( eight cancer targets successfully delivered ) . operations in the us aim to support existing relationships and generate new licensing and partnership opportunities .
, cso & vp business development of santaris pharma a / s , said
santaris pharma ' s lna drug platform provides the means to discover and develop novel drugs that potently and specifically bind rna - targets in previously inaccessible clinical pathways . usually , the objective is to inhibit the target to avoid protein synthesis , but in rana ' s case the lna drugs will be developed to selectively activate protein expression . as such , our agreement with rana is yet another example of how we seek to leverage the broad applicability of our drug platform through partnerships with the pharmaceutical industry .
by way of background , isis sued santaris ( a danish corporation not to be confused with isis’s fellow san diego - based firm santarus , recently bought by salix pharmaceuticals ) , accusing santaris of infringing isis patents to antisense compounds and methods of making the antisense compounds when santaris contracted to sell antisense drug discovery services and products to four pharmaceutical company customers in the united states . santaris moved for summary judgment on its affirmative defense that the alleged acts of infringement fell within the safe harbor provision of 35 u . s . c . § 271 .
the court denied santaris’s summary judgment motion , finding that santaris failed to provide undisputed evidence of the belief that the merck i court found was needed to properly claim the 271 ( e ) ( 1 ) safe harbor ( see above quote ) . instead , the isis court stressed that santaris’s supporting declaration by one of its officers provided only a general description of the collaborations between santaris and its customers . this , the court found , did not provide any detailed analysis of santaris’s uses of the allegedly infringing compounds , methods and processes to establish they rose to the level of a reasonable belief , as contemplated by merck i , as to a patented compound’s way of achieving a particular biological effect and , thus , failed to show that santaris fell under the protection of the 271 ( e ) ( 1 ) safe harbor .
micrornas are a newly discovered class of small regulatory molecules which control many biological processes in cells . in addition , micrornas are implicated in many diseases , such as cancer , viral infections , cardiovascular disease and neurological disorders and , therefore , represent a new class of targets for therapeutic intervention . santaris pharma
micrornas are a newly discovered class of small regulatory molecules which control many biological processes in cells . in addition , micrornas have been implicated in many diseases , such as cancer , viral infections , cardiovascular disease and neurological disorders and , therefore , represent a new class of targets for therapeutic intervention . santaris pharma
the agreement will see roche make an upfront cash payment of $ 250m to santaris shareholders and then further , conditional , milestone payments of up to $ 200m . the deal is expected to close later this month , when santaris ' danish operations will become the roche innovation center copenhagen .
santaris has developed its own flavor of antisense called locked nucleic acid technology , which the company claims is more effective in neutralizing targeted rna sequences .
according to krieg , “pharma is becoming more modality agnostic instead of just summarily dismissing oligos as drugs . they are primarily now just looking at these agents as drugs . ”
this gives the therapeutic increased potency , resistance to degradation , a long half life and ensures it is readily taken up by tissues , according to santaris .
santaris is based in denmark and performs research in san diego . it is unrelated to san diego - based santarus , which makes drugs for gastrointestinal ailments .
santaris pharma announced that it has commenced a phase i human volunteer trial of spc3649 ( lna - antimirtm - 122 ) , the world ' s first microrna medicine to be tested in man , according to the company . the study is being conducted by phaseonetrials a / s , copenhagen , and will include a maximum of 48 . . .
what to look for : new collaborations are in the works . phase ii data will be a major milestone for santaris as it advances a variety of trials .
commenting on its acquisition by roche , santaris ' president and ceo j . donald debethizy said the companies had complementary capabilities that will help them “realise breakthrough medicines” .
the drug produced only mild side effects , said michael r . hodges , vice president and chief medical officer of santaris , the study ' s senior author .
santaris pharma announced that it has commenced a phase i human volunteer trial of spc3649 ( lna - antimirtm - 122 ) , the world ' s first microrna medicine to be tested in man , according to the company . the study is being conducted by phaseonetrials a / s , copenhagen , and will include a maximum of 48 . . . more
“these study results are the culmination of over 6 years of microrna research at santaris pharma a / s , ” said michael r . hodges , md , vice president and chief medical officer at santaris pharma a / s . “the results of this study highlight miravirsen’s exceptional high barrier to resistance , long duration of action and good tolerability . miravirsen would be especially suitable for treatment of hard - to - treat patients , for example those patients who have already failed treatment with pegylated - interferon and ribavirin combination or protease inhibitor triple therapy . ” dr . hodges continued , “longer treatment durations of miravirsen are currently being tested in clinical trials in subjects who have failed initial therapy for hcv infection . ”
john reed , head of roche pharma research and early development , said :
today there are many disease targets that are very challenging or even impossible to reach with small molecules or antibodies .
two years after pfizer ( $ pfe ) inherited wyeth ' s discovery pact with denmark ' s santaris , its researchers have decided to significantly up the ante on their deal . the pharma giant is handing over $ 14 million in an upfront fee and promising up to $ 600 million more in milestones to expand the deal to develop rna - targeted drugs .
the lna drug platform and drug discovery engine developed by santaris pharma combines the company ' s lna chemistry with its targeted drug development capabilities to deliver lna - based drug candidates against rna targets , both mrna and microrna , for a range of diseases including infectious and inflammatory diseases , cardiometabolic disorders , cancer , and rare genetic disorders . the lna drug platform , according to santaris , overcomes the limitations of earlier antisense and sirna technologies to deliver potent single - stranded lna - based drug candidates across a multitude of disease states .
under the terms of the partnership the two companies will collaborate on the discovery , development and commercialisation of new medicines using santaris’ locked nucleic acid ( lna ) drug platform .
santaris claim that “ lna is the first true three - dimensional analogue of rna ” , which can be incorporated into oligonucleotides to enhance binding affinity to complementary rna sequences .
at least seven companies developing oligonucleotide - based drugs have licensed the technology from or partnered with santaris , which has an internal pipeline of six antisense molecules in the clinic .
maraganore agreed . “rnai therapeutics partnerships will be focused on product alliances . pharma has recently grown their interest in the rna therapeutics space but with an interest in products , not technology , ” he said .
“the acquisition of santaris provides roche the unique opportunity to merge their deep expertise in disease biology , target selection , toxicology , formulation , and drug delivery with the most extensive experience in designing and producing lna oligonucleotides , a technology that roche believes will redefine rna - targeting medicine in the future , ”  a santaris spokesperson told in - pharmatechnologist . com .
the acquisition marks an acceleration in roche ' s interest in both rnai research and santaris , after the two companies struck a more limited $ 148m discovery and development deal in january .
the court also cited the santaris officer’s previous statement to the pto that , “ ( t ) he majority of [ santaris ' s ] collaborators have taken broad licenses to our proprietary lna platform in order to discover , develop , and commercialize new lna - based drugs against rna targets associated with disease , ” observing that the reference to selling “platform” technology so that another company could develop and discover drug candidates , suggested that santaris was using its technology for “basic research” not covered under the § 271 ( e ) ( 1 ) safe harbor .
santaris was the first company to bring a mirna - targeting molecule into the clinic . the company ' s miravirsen , an lna - modified anti - mirna that targets hepatocyte mir - 122 , is in phase ii testing to treat hcv . in 2013 , santaris published phase iia data showing that miravirsen resulted in a dose - dependent reduction in hcv rna levels . 8
santaris claims its lna platform enables specific targeting and regulation of micrornas ( mirnas ) and messenger rnas ( mrnas ) , which is an area wyeth has been making efforts to establish itself in .
naarden , the netherlands - 4 august 2014 - forbion capital partners , the leading dutch vc firm investing in world - class healthcare technologies announces the sale of its portfolio company , santaris pharma a / s for a total consideration of up to $ 450 million , of which an upfront cash payment of $ 250 million and additional contingent payments of up to $ 200 million based on the achievement of certain predetermined milestones .
s proprietary lna drug chemistry and the screening platform will be developed by a collaborative research consortium led by santaris pharma and the biotech research & innovation centre ( bric ) at the university of copenhagen . other members of the consortium are the nucleic acid centre ( nac ) , university of southern denmark , h . lundbeck a / s , the danish headquartered pharmaceutical company and ribotask a / s , the danish reagents company .
hoersholm , denmark / san diego , california — santaris pharma a / s , a privately - held biopharmaceutical company focused on developing rna - based drugs targeted to disease - related mrnas and micrornas , today announced it has established operations in the united states . internally and through its partners , the company has a robust drug development pipeline including programs to treat metabolic disorders , infectious and inflammatory diseases , cancer and rare genetic disorders .
developed using santaris pharma a / s proprietary locked nucleic acid ( lna ) drug platform , miravirsen is an inhibitor of mir - 122 , a liver specific microrna that the hepatitis c virus requires for replication . miravirsen is designed to recognize and sequester mir - 122 , making it unavailable to the hepatitis c virus . as a result , the replication of the virus is effectively inhibited and the level of hepatitis c virus is profoundly reduced .
santaris got $ 17 million in cash and equity from wyeth for their original pact struck in early 2009 . the revised deal includes potential royalty payments for drugs promising to hit up to 10 rna targets .
nevertheless , although accepting some of santaris’s legal arguments , the isis court cited santaris’s failure to provide undisputed evidence of such knowledge or belief in denying santaris’s summary judgment motion . the court found instead that fact issues remained as to whether santaris ' s collaboration agreements were
reasonably related
to the type of information submitted to the fda—that is , whether it was
objectively reasonable for a party in [ santaris ' s ] . . . situation to believe that there was a decent prospect that the accused activities would contribute , relatively directly , to the generation of the kinds of information that are likely to be relevant in the processes by which the fda would decide whether to approve the product in question
[ citing merck i , 545 u . s . at 200 - 01 ( district court jury instruction ) ] . accordingly , the court found that this fact question regarding what was reasonable , should be left to the trier of fact , as is customary for most questions involving a question of what is reasonable .
called miravirsen , the drug reduced the virus by a factor of 100 to 1 , 000 in the phase 2a trial , santaris said . study results were published wednesday in the new england journal of medicine .
the swiss company , which exited the rnai field in 2010 as part of an r & d restructure , believes santaris ' rna - targeting technology could underpin the discovery and development of a new class of medicines .
santaris ' pipeline of rnai - or ' gene silencing ' - drugs are based on its locked nucleic acid ( lna ) platform and its lead candidate is miravirasen , a novel hepatitis c treatment in phase ii trials .
, ceo of isarna therapeutics said :
in optimizing our cancer immunotherapeutics , we see santaris ' lna approach as a unique enabling technology to support the efficacy profile of our novel products targeted at breakthrough status diseases .
under the agreement of the transaction , roche will make an upfront payment of $ 250 million in cash to santaris’ shareholders as well as up to $ 250 million in additional contingent payments once specific predetermined milestones are met .
every drug is targeted at a precise rna sequence in messenger or microrna ,
says mccullagh . for mccullagh , the whole field offers an opportunity that can one day rival monoclonal antibodies . and that message has not been lost in the pharma world .
shire’s business development and licensing team scooped the award , this year for the pace and strength of its activities , including the acquisition of viropharma ( jan 2014 ; $ 4 . 2bn ) , lumena pharmaceuticals ( may 2014 ; $ 260m ) and fibrotech ( may 2014 , $ 75m ) . its portfolio was expanded by licencing agt - 182 from armagen ( jul 2104 ; $ 225m ) and rebalanced by selling distribution rights for estrace to trimel pharma ( july 2014 ; $ 41m ) and dermagraft to organogenesis ( jan 2014 ; $ 300m ) . partnerships were also inked with prasco labs ( fosrenol distribution ; oct 2013 ) , santaris pharma ( lna drugs ; aug 2013 ) and argen - x ( drug discovery partnership ; june 2014 ) .
such therapies offer a number of benefits over traditional small molecule and monoclonal antibody approaches , according to santaris , including reducing candidate failure due to pharmacokinetic / toxicology predictability , and increased chemistry , manufacturing and control ( cmc ) efficiency .
dr . john reed , head of pharma research and early development ( pred ) at roche stated :
we are very pleased with our new partnership with santaris . we believe the lna drug platform provides the means to discover novel drugs against a range of targets of high clinical relevance that are difficult – or impossible - to target with other drug platforms . as such , the partnership will increase our ability to discover and develop important novel medicines that can address significant unmet needs in critical therapeutic areas
.
exiqon’s product offering includes lna™ amidites and lna™ oligonucleotides for the research and development of pharmaceutical products . exiqon has the exclusive right to supply such products except for use in the research and development of pharmaceutical products containing lna™ as the active ingredient . today’s decision by the arbitration court establishes exiqon’s non - exclusive right to supply these products also for the research and development of pharmaceutical products containing lna™ as the active ingredient . santaris pharma’s request that exiqon should be prevented from supplying lna™ products for such use was dismissed .
) . the positive rulings by the united states patent and trademark office ( uspto ) cover two key santaris pharma a / s
imanishi
patents , u . s . pat . no . 6 , 268 , 490 ( the
' 490 patent
) and u . s . pat . no . 6 , 770 , 748 , ( the
' 748 patent
) , which claim rights to the locked nucleic acid ( lna ) or bicyclic nucleic acid ( bna ) chemical structure used for developing antisense molecules .
the united states patent and trademark office ( uspto ) revoked the ex parte re - examination of the ' 490 patent and provided a notice of intent to issue a reexamination certificate that confirms the patentability of all claims of the ' 490 patent owned by santaris pharma a / s and is not subject to appeal . in addition , the uspto issued an action closing prosecution in the inter - partes re - examination of ' 748 patent , which is a continuation - in - part of the ‟490 patent , confirming all of the original claims .
the expanded alliance with pfizer is a result of our successful collaboration over the last two years and provides further evidence that our lna drug platform is rapidly becoming the technology - of - choice for partners interested in developing rna - targeted medicines ,
said soeren tulstrup , president and ceo of santaris pharma a / s .
the lna drug platform is well positioned to deliver viable drug candidates today , and we are excited to expand our relationship with pfizer to pursue our goal of making rna - targeted drugs for important diseases a reality .
santaris pharma a / s lna drug platform combines the company ' s proprietary lna chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single - stranded lna - based drug candidates across a multitude of disease states including infectious and inflammatory diseases , cardiometabolic disorders , cancer , and rare genetic disorders . the unique combination of pharmaceutical properties , small size and very high affinity of lna - based drugs allows this new class of antisense drugs to potently and specifically inhibit rna - targets in many different tissues without the need for complex delivery vehicles .
this written announcement contains forward - looking statements , identified by the use of words such as
believes ,
expects ,
may ,
will ,
should
,
potential ,
anticipates ,
plans
or
intends
and similar expressions . such forward - looking statements involve risks , uncertainties and other factors that may cause actual results , events or developments to be materially different from the future results , events or developments indicated in this announcement . such factors include , but are not limited to the timing , success and cost of clinical studies ; the ability to obtain regulatory approval of products , market acceptance of and future demand for santaris pharma products and the impact of competitive products and pricing . these factors should be considered carefully and readers are cautioned not to place undue reliance on such forward - looking statements . no assurance can be given that the future results covered by the forward - looking statements will be achieved . all information in this press release is as of the date of this press release and santaris pharma does not intend to update this information .
one of the major challenges facing oligonucleotide therapeutics is the effective and broad delivery to target tissues . in the field of sirna therapeutics , both chemical modification and liposomal formulation are being widely explored as means to overcome this challenge . in this presentation , santaris pharma researchers show that in preclinical models short , single stranded lna oligonucleotides can be administered intravenously as naked molecules and are broadly taken up by a wide range of targeted tissues ( e . g . , kidney , liver , bone marrow , spleen , intestine , skin , lymph nodes , and pancreas ) .
in a comment , president and ceo of exiqon , lars kongsbak said : “ exiqon is committed to provide best in class products for the detection of nucleic acids using our lna™ technology . this has allowed us to become a leader in our markets , and serves as the foundation for exiqon’s commitment to develop , and help propel the development of , novel molecular diagnostic products , including companion diagnostics , for which we provide easy access to our proprietary technologies through licensing . proceedings against santaris pharma were an unfortunate , but necessary , step towards realizing our business goals . ”
fda - regulated firms - - drug , device , biologic or otherwise - - on both sides of the patent aisle concerned with the bounds of the “safe harbor” exception to patent infringement under 35 u . s . c . § 271 ( e ) ( 1 ) can learn several key lessons from the recent decision in isis pharmaceuticals , inc . v santaris pharma a / s corp . ( hereafter : “ isis ” ) , particularly how to properly prove the safe harbor defense once the litigation unfolds and also when the harbor provides shelter from post - approval patent storms .
the scoop : santaris has been breaking new ground with its advancement of a microrna therapy into the clinic in late may . a successful proof - of - concept trial for hepatitis c is being billed as a potential medical breakthrough , offering a key to modulating networks of genes .